| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3281648 | Clinical Gastroenterology and Hepatology | 2014 | 28 Pages |
Abstract
Among patients with quiescent UC and increased levels of FC, increasing the dose of mesalamine by 2.4 g/day reduced fecal concentrations of calprotectin to those associated with lower rates of relapse. Clinicaltrials.gov number: NCT00652145
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Mark T. Osterman, Faten N. Aberra, Raymond Cross, Steven Liakos, Robert McCabe, Ira Shafran, Douglas Wolf, Robert Hardi, Lisa Nessel, Colleen Brensinger, Erin Gilroy, James D. Lewis, DEAR Investigators DEAR Investigators,